suramin has been researched along with Local Neoplasm Recurrence in 5 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the toxicity, efficacy, and pharmacology of suramin in patients with recurrent or progressive recurrent high-grade gliomas." | 9.09 | Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas. ( Fisher, J; Grochow, LB; Grossman, SA; Lesser, G; Phuphanich, S; Piantadosi, S; Rozental, J, 2001) |
| "Suramin is a polysulfonated naphthylurea that inhibits the function of growth factors and growth factor receptors implicated in glioma progression, angiogenesis, and radioresistance." | 6.71 | Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study. ( Carson, KA; Gilbert, MR; Grossman, SA; Hochberg, FH; Laterra, JJ; Lesser, GJ, 2004) |
| "To determine the toxicity, efficacy, and pharmacology of suramin in patients with recurrent or progressive recurrent high-grade gliomas." | 5.09 | Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas. ( Fisher, J; Grochow, LB; Grossman, SA; Lesser, G; Phuphanich, S; Piantadosi, S; Rozental, J, 2001) |
| "Suramin is a polysulfonated naphthylurea that inhibits the function of growth factors and growth factor receptors implicated in glioma progression, angiogenesis, and radioresistance." | 2.71 | Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study. ( Carson, KA; Gilbert, MR; Grossman, SA; Hochberg, FH; Laterra, JJ; Lesser, GJ, 2004) |
| "Suramin is an antitrypanosomal agent with antineoplastic activity, but with serious systemic side effects." | 2.71 | Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma. ( Banks, RE; Cranston, D; Crew, J; Harris, AL; Joel, SP; Jones, A; Le Monnier, K; Ord, JJ; Roberts, IS; Rogers, MA; Streeter, E, 2005) |
| "In large part, ovarian cancer's lethality is due to the fact that most women are diagnosed with disease that is widespread throughout the abdomen and pelvis." | 2.39 | Promising new developments in the systemic treatment of ovarian cancer. ( Reed, E, 1994) |
| "The term "hormone-refractory" prostate cancer has evolved to include patients with a spectrum of diseases." | 2.39 | Hormone-refractory (D3) prostate cancer: refining the concept. ( Kelly, WK; Scher, HI; Steineck, G, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Laterra, JJ | 1 |
| Grossman, SA | 2 |
| Carson, KA | 1 |
| Lesser, GJ | 1 |
| Hochberg, FH | 1 |
| Gilbert, MR | 1 |
| Ord, JJ | 1 |
| Streeter, E | 1 |
| Jones, A | 1 |
| Le Monnier, K | 1 |
| Cranston, D | 1 |
| Crew, J | 1 |
| Joel, SP | 1 |
| Rogers, MA | 1 |
| Banks, RE | 1 |
| Roberts, IS | 1 |
| Harris, AL | 1 |
| Reed, E | 1 |
| Scher, HI | 1 |
| Steineck, G | 1 |
| Kelly, WK | 1 |
| Phuphanich, S | 1 |
| Lesser, G | 1 |
| Rozental, J | 1 |
| Grochow, LB | 1 |
| Fisher, J | 1 |
| Piantadosi, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study of Suramin and Concurrent Radiation Therapy in Newly Diagnosed Glioblastoma Multiforme[NCT00004073] | Phase 2 | 54 participants (Anticipated) | Interventional | 1999-12-31 | Completed | ||
| A Phase I Study of Intravesicular Suramin in Recurrent Superficial Bladder Cancer[NCT00006476] | Phase 1 | 15 participants (Anticipated) | Interventional | 2000-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for suramin and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Promising new developments in the systemic treatment of ovarian cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Female; Granulocyte Colo | 1994 |
Hormone-refractory (D3) prostate cancer: refining the concept.
Topics: Aminoglutethimide; Clinical Trials as Topic; Cortisone; Dexamethasone; Drug Therapy, Combination; Hu | 1995 |
3 trials available for suramin and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study.
Topics: Aged; Brain Neoplasms; Confidence Intervals; Female; Follow-Up Studies; Glioblastoma; Humans; Male; | 2004 |
Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Transitiona | 2005 |
Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Female; Glioma; Humans; Male; | 2001 |